07:00 , Apr 14, 2016 |  BC Innovations  |  Emerging Company Profile

Thinking about HDAC2

Mark Zipkin, Staff Writer  Rodin Therapeutics Inc. is developing selective HDAC2 inhibitors to treat cognitive impairment in Alzheimer's disease (AD) without causing the serious side effects associated with pan- HDAC - a strategy that netted...
07:00 , Apr 30, 2015 |  BC Innovations  |  Distillery Techniques

Therapeutics: Theiler's murine encephalomyelitis virus (TMEV)-infected mouse model of infection-induced epilepsy

Disease models TECHNOLOGY: Animal models A TMEV-infected mouse model could could help assess and predict the effects of anti-seizure therapeutics on infection-induced epilepsy, an infrequently occurring condition with little treatment history. Mice infected with TMEV...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Epilepsy Not applicable In vitro and rodent studies suggest analogs of octanoic acid could help treat epilepsy. Chemical synthesis and electrophysiological testing in a rat...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Epilepsy Not applicable In vitro and rodent studies suggest analogs of octanoic acid could help treat epilepsy. Chemical synthesis and electrophysiological testing in a rat...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

DP-VPA regulatory update

D-Pharm said partner Jiangsu NHWA received notice that China Food and Drug Administration (CFDA) granted Fast Track designation to DP-VPA to treat epilepsy. D-Pharm said Jiangsu NHWA plans to begin a Phase I trial in...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Expansion of primitive, CD34+ cord blood cells with histone deacetylase (HDAC) inhibitors Mouse and ex vivo studies suggest HDAC inhibitors could be used to expand...
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms In vivo reprogramming of astrocytes to neuroblasts Mouse studies suggest proliferating neuroblasts generated in vivo from reprogrammed astrocytes could help treat...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Clinical News

Scyllo-inositol: Phase II started

Elan began the double-blind, placebo-controlled, U.S. Phase II ELND005-BPD201 trial to evaluate oral ELND005 as an adjunctive maintenance treatment to lamotrigine or valproic acid in about 400 patients. Elan said the trial start triggered an...
07:00 , May 28, 2012 |  BC Week In Review  |  Company News

D-Pharm, Thrombotech deal

D-Pharm will merge with stroke company Thrombotech in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In February, D-Pharm said it was in negotiations...
01:19 , May 25, 2012 |  BC Extra  |  Company News

D-Pharm, Thrombotech to merge

D-Pharm Ltd. (Tel Aviv:DPRM) will merge with stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal. Shareholders of Thrombotech will own 60% of the combined company, while D-Pharm shareholders will own 40%. In...